CHARM

20 Aug CHARM

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial

McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the CHARM investigators

CHARM participants 618 centers in 26 countries

Inclusion and exclusion criteria

Inclusion criteria:

• Age >= 18 years

• Symptomatic heart failure for at least 4 weeks (New York Heart Association Class II-IV)

Key exclusion criteria:

• S-creatinine >=265 μmol/L (>=3mg/dL)

• S-potassium >=5.5mmol/L

• Bilateral renal artery stenosis

• Symptomatic hypotension

• ARB within two weeks

Κατεβάστε την πλήρη παρουσίαση σε μορφή διαφανειών Powerpoint.